United States Patent 8,673,927 (US8673927): Scope, Claim Architecture, and Landscape for the Metformin Combination in Type II Diabetes
What does US 8,673,927 claim, in plain terms?
US 8,673,927 claims methods of treating Type 2 diabetes mellitus (and also pre-diabetes in dependent independent claim formatting) using an oral, specific small molecule xanthine in combination with metformin. The drug combination scope is defined tightly by:
- The identity of the xanthine compound:
- 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
- The administration route:
- The metformin dose regime, split by immediate-release vs delayed-release
- The xanthine oral dose range and specific dose exemplars (notably 0.5 mg up to 50 mg, with multiple claims narrowing to 2.5 mg to 10 mg, and repeated anchor values such as 2.5 mg, 5 mg, 10 mg)
The claim set you provided is entirely directed to combination therapy methods, not compound composition claims, not formulations, and not manufacturing processes.
What is the core claim structure and how broad is each claim tier?
Claim set overview (independent-method claims)
Based on the claim text provided, the patent has at least these independent-method claim “families”:
- Claim 1: Type II diabetes treatment; xanthine + metformin; IR and DR metformin dosing windows.
- Claim 10: Type 2 diabetes or pre-diabetes; xanthine + metformin; explicit metformin single-dose/daily total ranges and delayed-release options.
- Claim 18: Type II diabetes treatment; narrowed xanthine daily dose (2.5 mg to 10 mg) + metformin (no metformin window detail in your excerpt beyond “pharmaceutically effective amount”).
- Claim 19: Type II diabetes treatment; xanthine daily dose fixed at 5 mg + metformin.
- Claim 20: Type 2 diabetes or pre-diabetes; xanthine + metformin; xanthine dose ranges (0.5 mg to 50 mg) with dependent claim narrowing.
Everything else (claims 2-9, 11-17, 21-26) is dose-range and specific-dose narrowing of the same combination method.
Dose-defined “coverage spine” (xanthine + metformin)
The patent’s enforceable “spine” is the pairing of:
- Xanthine: oral dose range and exemplified fixed doses (0.5 mg to 50 mg; emphasis on 2.5 mg to 10 mg and 2.5 mg/5 mg).
- Metformin: explicit dosing windows for IR and DR and daily total ranges.
This design creates a layered structure:
- Broadest tier: claim 1 and claim 10/20-like constructs using the full xanthine range and metformin dosing frameworks.
- Mid tier: claims limiting xanthine daily dose to 2.5-10 mg.
- Narrow tier: claims requiring fixed xanthine daily dose such as 5 mg (and in dependent claims, 1 mg, 2.5 mg, 5 mg, 10 mg selections).
How does the metformin dosing scope operate?
Metformin immediate-release (IR) dosing windows in Claim 1
Claim 1 defines metformin dosing for Type 2 diabetes as:
- 300 mg to 1000 mg metformin once or twice a day
(interpretable as daily total potentially spanning 300 mg to 2000 mg/day, but the literal claim is “once or twice a day” with the same mg per dose)
- or delayed-release (DR) metformin:
- 500 mg to 1000 mg once or twice a day or
- 500 mg to 2000 mg once a day
So Claim 1 has dual metformin regimes:
- IR: 300–1000 mg per administration, once or twice daily
- DR: 500–1000 mg per administration, once or twice daily OR 500–2000 mg once daily
Metformin IR/DR specificity in Claim 10
Claim 10 defines metformin combination dosing for Type 2 diabetes or pre-diabetes with more explicit arithmetic boundaries.
It permits either:
Option A: metformin immediate-release as single dose(s) with total daily dose 500–2850 mg
- single dose of 500 mg, 850 mg, or 1000 mg
- total daily dose 500–2850 mg
Option B: delayed-release metformin dosing with specific per-dose levels
- delayed-release metformin:
- 500 mg, 1000 mg, 1500 mg, or 2000 mg
- (your excerpt frames this as a “delayed release form” option tied to combination use; the total daily dose constraint is not stated as a single numeric range in the excerpt the way it is for IR)
Claim 1 vs Claim 10: practical coverage difference
- Claim 1’s metformin scope is organized around dose-per-administration and once vs twice daily.
- Claim 10’s metformin scope is organized around:
- allowed single-dose levels (500/850/1000 for IR)
- and a total daily dose ceiling structure (500–2850).
From an infringement-navigation standpoint, Claim 10 can be easier to map because it explicitly sets a total daily dosing band for IR.
How does the xanthine dosing scope operate?
Global xanthine dose ranges used across claims
Across claim 1 and claim 10/20 and their dependents, the xanthine dosing appears repeatedly in three banding modes:
- Wide range: 0.5 mg to 50 mg
- Mid range: 2.5 mg to 10 mg
- Fixed points: 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, plus dependent claims that lock to subsets such as 1 mg/2.5 mg/5 mg or 2.5 mg/5 mg, and independent claims that lock to 5 mg.
Claim 1 xanthine dose tiers
Claim 1 itself does not, in your excerpt, include the xanthine dose window in the independent statement beyond “oral amount.” The dose windows appear in dependents:
- Claim 2: xanthine daily dose 2.5 mg to 10 mg
- Claim 3: xanthine oral dosage 0.5 mg to 50 mg
- Claim 4: xanthine daily dose 2.5 mg to 10 mg
- Claim 5: xanthine oral dosage is one of 0.5, 1, 2.5, 5, 10 mg
- Claim 6: xanthine oral dosage is one of 1, 2.5, 5 mg
- Claim 7: xanthine oral dosage is 2.5 or 5 mg
- Claim 8: xanthine oral daily dose 2.5 mg to 50 mg
- Claim 9: xanthine oral daily dose 5 mg
Claim 10/20 xanthine tiers
Claims 11-17 (dependents of claim 10) mirror the same banding:
- Claim 11: xanthine oral dosage 0.5 mg to 50 mg
- Claim 12: xanthine oral dosage 2.5 mg to 10 mg
- Claim 13: xanthine oral dosage one of 0.5, 1, 2.5, 5, 10 mg
- Claim 14: xanthine oral dosage one of 1, 2.5, 5 mg
- Claim 15: xanthine oral dosage 2.5 or 5 mg
- Claim 16: xanthine oral dosage 2.5 mg to 50 mg
- Claim 17: xanthine oral daily dose 5 mg
Claims 21-26 (dependents of claim 20) again track the same pattern:
- Claim 21: xanthine oral dosage 2.5 to 50 mg
- Claim 22: xanthine oral dosage 2.5 to 10 mg
- Claim 23: xanthine oral dosage one of 0.5, 1, 2.5, 5, 10 mg
- Claim 24: xanthine oral dosage one of 1, 2.5, 5 mg
- Claim 25: xanthine oral dosage 2.5 or 5 mg
- Claim 26: xanthine oral daily dose 5 mg
What does the claim scope mean for design-around risk?
The claim drafting indicates design-around leverage is limited because the xanthine dose is claimed both:
- by broad range (0.5–50 mg)
- by mid range (2.5–10 mg)
- and by specific fixed doses (including 1 mg, 2.5 mg, 5 mg, 10 mg)
To avoid the claim, a product would need to fall outside the claimed xanthine dosing windows and also outside the metformin dose regimes as claimed (IR vs DR). The metformin claim complexity (IR total daily band in claim 10; IR/DR “once or twice” structures in claim 1) means design-around must be engineered across both axes.
How the claims treat indications: Type 2 diabetes vs pre-diabetes
From the excerpt:
- Claim 1 and claims 18-19 are oriented to Type II diabetes mellitus.
- Claim 10 and claim 20 are oriented to Type 2 diabetes or pre-diabetes.
This matters because, in enforcement terms, pre-diabetes use may only be captured by the claims that expressly include pre-diabetes (claim 10/20 and their dependents 11-17 / 21-26).
Claim chart style mapping (what must be present to infringe)
A method falls within the claimed combination scope if it performs all steps recited in a given claim set.
Infringement checklist for Claim 1 (as excerpted)
A defendant must:
- Treat Type II diabetes mellitus.
- Administer orally:
- xanthine: 1-[(4-methyl-quinazolin-2-yl)-methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
- metformin: with dose structure specified (IR 300–1000 mg once or twice daily; or DR dosing windows)
- The xanthine dose is constrained in dependent claims (2-9) but Claim 1 itself requires “pharmaceutically effective oral amount” in the independent statement.
Infringement checklist for Claim 10
A defendant must:
-
Treat Type 2 diabetes or pre-diabetes.
-
Administer the oral xanthine in combination with metformin with one of the specified metformin dosing structures:
- IR: single-dose level 500/850/1000 mg and total daily 500–2850 mg
- or delayed-release: 500/1000/1500/2000 mg (as per the excerpt’s DR framing)
-
Xanthine dosing constraints apply via dependents (11-17) and potentially by independent claim 10’s “therapeutically effective dose” wording.
What is the patent landscape beyond US 8,673,927, using only claim text provided?
No publication dates, application family history, assignee, priority, related patents, citation lists, or prosecution history were provided in the prompt. Without that data, a complete US landscape analysis (overlap with other patents, remaining life, continuation status, terminal disclaimer, blocking patents in the same compound class, or litigation posture) cannot be produced.
So the landscape analysis below is limited to scope-based competitive interpretation derived from the claims themselves, not an evidentiary landscape mapped to other documents.
Competitive implications for R&D and portfolio strategy (scope-based)
Combination specificity is the value lever
The claims do not cover:
- xanthine monotherapy
- injectable dosing routes
- other biguanides or GLP-1 combinations in the excerpt
- formulations (no formulation claims included in your text)
The enforceable differentiation is the specific xanthine + metformin method pairing, with dose-defined metformin IR/DR.
Dose-anchoring suggests the inventors found a therapeutic window
The repeated fixed xanthine daily dose values (especially 5 mg) across multiple claims indicate the patent is structured around a likely clinical regimen and is intended to capture:
- flexible dosing within a band (0.5–50 mg)
- but also the “best mode” or most probable development doses (2.5 mg and 5 mg, with 1 mg and 10 mg as alternates)
Pre-diabetes inclusion expands enforcement coverage for early-stage labeling
Because claim 10 and claim 20 explicitly include pre-diabetes, any clinical strategy or label position that uses the combination for pre-diabetes is more exposed under the claims than a strategy confined to established Type 2 diabetes.
Key Takeaways
- US 8,673,927 claims oral combination treatment methods for Type II diabetes, and in some claims also pre-diabetes, using a specific xanthine plus metformin.
- The enforceable scope is defined by two dose axes:
- xanthine: 0.5 mg to 50 mg, with frequent emphasis on 2.5 mg to 10 mg and fixed doses 1, 2.5, 5, 10 mg (and multiple claims anchored to 5 mg).
- metformin: IR dosing windows (claim 1) or IR single-dose and total daily band (claim 10), plus DR dosing options.
- Claim 10/20 capture pre-diabetes use; claim 1 and claims 18-19 focus on Type II diabetes.
- A design-around must shift both xanthine dose and metformin IR/DR dosing to fall outside the claimed combinations; partial changes are unlikely to eliminate exposure given the layered dose narrowing.
FAQs
1) Does US 8,673,927 claim the xanthine compound itself (composition of matter)?
No in the provided claim set; it claims methods of treating diabetes using the specified xanthine orally in combination with metformin.
2) What xanthine doses are expressly called out in the dependent claims?
The dependents list specific xanthine oral dosages including 0.5 mg, 1 mg, 2.5 mg, 5 mg, and 10 mg, plus subsets like 1/2.5/5 mg and 2.5 or 5 mg, and a daily dose of 5 mg.
3) How does the metformin dosing differ between claim 1 and claim 10?
Claim 1 sets IR and DR windows using dose per administration with once vs twice daily language. Claim 10 sets IR exposure via allowed single-dose levels (500/850/1000 mg) and a total daily dose range (500–2850 mg), plus DR dose levels.
4) Is pre-diabetes covered?
Yes. Claims structured like claim 10 and claim 20 include “Type 2 diabetes or pre-diabetes.” Claims 1, 18, and 19 in the excerpt are framed as Type II diabetes.
5) What is the most prominent xanthine regimen in the claim set?
The claim set repeatedly anchors to 5 mg daily, including explicit dependent claims and an independent claim where the xanthine daily dose is 5 mg.
References
- United States Patent 8,673,927. (Claim text provided in prompt; no bibliographic metadata included).
